Compass Pathways expects the hourly reimbursement rate for COMP360 administration to be higher than the rate currently paid for Spravato.

Overview Debates Related claims Topics Sources

Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.

Compass Pathways CEO Kabir Nath stated at the STAT Summit that the company will go slow before it goes fast ahead of the COMP360 FDA submission to avoid early negative patient or provider experiences.

In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.

Compass Pathways CEO Kabir Nath stated on October 14, 2026, that the company plans to complete its rolling FDA submission for COMP360 synthetic psilocybin treatment in the fourth quarter of 2026.

Compass Pathways CEO Kabir Nath stated that COMP360 clinical trial session recordings revealed patients spent approximately 80% of session time in silence after the company deliberately separated psychotherapy from trial protocols.

Compass Pathways is engaging commercial insurers and CMS regarding reimbursement mechanisms for clinical monitoring required during COMP360 psilocybin treatment sessions.

COMP360 psilocybin treatment holds Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

The Trump administration initiative to advance government-funded ibogaine research follows calls from veterans and experts for strict safety standards on psychedelic treatments.

The U.S. Food and Drug Administration has opened a public docket seeking feedback by November 20, 2026 on trial design, dose selection, patient eligibility, safety monitoring, and oversight for clinical trials of ibogaine.

Federal funding for ibogaine clinical trials is justified by its therapeutic potential

Due to the lack of approved medical access in the U.S., Americans are paying between $5,000 and $20,000 to travel to specialized clinics in Mexico for ibogaine treatments.

Psychedelics should be legal for therapeutic use

President Donald Trump issued an executive order in April 2026 titled "Accelerating Medical Treatments for Serious Mental Illness," which directed federal agencies to accelerate research into psychedelic medicine.

The Food and Drug Administration previously issued finalized guidance in July 2026 titled "Psychedelic Drugs: Considerations for Clinical Investigations" to assist sponsors developing psychedelic drugs.

Ibogaine is classified as an illegal Schedule I controlled substance under United States law and is unavailable for medical use in the country.

The U.S. Food and Drug Administration announced a request for information on October 5, 2026, seeking public feedback on early-phase clinical trial designs for ibogaine drug products.

The Food and Drug Administration is seeking public input on specific ibogaine trial parameters, including a proposed starting dose not exceeding 10 mg/kg and the use of small, sequential dose-ascending groups.

The Food and Drug Administration opened a public docket seeking feedback on ibogaine trial protocol elements, including dose selection, patient eligibility, safety monitoring, and study-stopping rules, with comments closing on November 20, 2026.

The Schedule I controlled substance classification of ibogaine is justified

Experts and veterans have called for strict safety standards on psychedelic treatments.